Schrödinger, Inc. (Nasdaq: SDGR) has announced initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505, targeting patients with relapsed/refractory B-cell malignancies. The study results, which were presented at the European Hematology Association Annual Congress, indicate that SGR-1505 is safe, well tolerated, and shows clinical activity, with responses noted in various histologies including chronic lymphocytic leukemia and Waldenström macroglobulinemia. As of May 13, 2025, 49 patients were enrolled and evaluable for safety. Schrödinger's management will host a webcast to discuss these findings and the proposed Phase 2 dose later today.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.